910 Clopper Rd #200
About Miltenyi Biotec
We empower great science. For over 30 years, Miltenyi Biotec has provided innovative tools, instruments, and solutions that advance biomedical research and cellular therapy. We are 3,000 scientists, engineers, physicians, support specialists, marketers and more – all dedicated to improving scientific understanding and impacting human lives. At our headquarters campus and offices worldwide, fresh ideas become unique products.
Everyone at Miltenyi Biotec is committed to making cancer history. Watch the video to see what motivates our scientists, engineers, IT professionals, and marketeers. Learn why they like working at Miltenyi Biotec.
22 articles with Miltenyi Biotec
Miltenyi Biotec announced the immediate availability of its new CliniMACS Prodigy® Adherent Cell Culture System.
Miltenyi Biotec today announces the UltraMicroscope Blaze.
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.
Miltenyi Biotec today launches the SARS-CoV-2 PepTivator Peptide Pools, a new addition to its popular PepTivator Portfolio specifically developed to help researchers currently investigating COVID-19.
IsoPlexis Continues Progress on Precision CAR-T cell Characterization with Recent Data Sets & Miltenyi Biotec, Inc. Technology Note
IsoPlexis illustrates progress in CAR-T development & bioprocessing with funding, recent data sets, and co-marketing technology note with Miltenyi Biotec, Inc.
Cellenion and Miltenyi Biotec Sign Co-Marketing Agreement to Provide a Time and Cost-Efficient Solution for the Development of Monoclonal Cell Lines
SCIENION AG and Miltenyi Biotec GmbH today announced that Scienion’s affiliate Cellenion and Miltenyi Biotec have signed a co-marketing agreement.
Lentigen Technology, A Miltenyi Biotec Company, Acquires University of Maryland, Baltimore CAR-T Cell Start-Up, Living Pharma
Miltenyi Biotec, Inc. And Cesca Therapeutics' Subsidiary Totipotentrx Announce Multi-Year Commercial Agreement For Bone Marrow Transplantation
Miltenyi Biotec, Inc. Receives FDA Approval For Clinimacs® CD34 Reagent System For Prevention Of Graft-Versus-Host Disease In The Treatment Of Acute Myeloid Leukemia
Miltenyi Biotec, Inc. Partners With Terso Solutions, Inc. for a Fully Automated, On-Site Inventory Management Program
Miltenyi Biotec, Inc.: Heart Disease and Cellular Therapy: Start of Phase III Clinical Trial "PERFECT" Using Autologous CD133+ Bone Marrow Stem Cells
Miltenyi Biotec, Inc.'s Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings
Miltenyi Biotec, Inc. Release: The New MACSQuant(TM) Analyzer Combines Cell Enrichment and Flow Cytometry